In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

The sST2 level in prediction of heart failure decompensation in patients with acute myocardial infarction

Session HFA Discoveries - ePosters

Speaker Iulia Rodionova

Event : HFA Discoveries 2020

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Coronary Artery Disease: Treatment, Revascularization
  • Session type : ePosters

Authors : I Rodionova (Kharkiv,UA), YV Hylova (Kharkiv,UA), I Kutya (Kharkiv,UA), MP Kopytsya (Kharkiv,UA), AV Kobets (Kharkiv,UA)

Authors:
I Rodionova1 , YV Hylova1 , I Kutya1 , MP Kopytsya1 , AV Kobets1 , 1L.T.Malaya Institute of Therapy - Kharkiv - Ukraine ,

Citation:

Adverse outcomes of myocardial infarction force us to investigate prediction the adverse course of acute myocardial infarction (AIM) using modern biomarkers. Soluble ST2 (sST2) could be considered as such possible marker.

The purpose of the study was to investigate the frequency of undesirable events in dependence of initial level of sST2 in patients with A?M.

Materials and methods. 103 patients with A?M with the ST segment elevation was included in the study, with 75 (72.8%) males, average age of 61.85 ± 12.23 years. The initial level of sST2 was determined at admission by ELISA. The endpoint was the decompensation of heart failure (HF). The groups of patients were distributed in 2 groups depending on the initial level of sST2 with the threshold 35 ng/ml.

Results. Patients with an initial higher level of sST2 (= 35 ng / ml – the first group) were characterized by a higher incidence of achieving the endpoint that was detected in 25 (44.6%) patients versus 10 (21.3%) in the second group with sST2 <35 ng / ml (?2 = 6.22, p = 0.01). The number of adverse events in patients in the 2nd group receiving bisoprolol in different doses (2.5 mg vs =5mg), no significant differences were found (?2 = 0.70, p = 0.79), but in the first group (sST2 = 35 ng/ml), it was (?2 = 6.62, p = 0.01).

Conclusions. The initial level of sST2 = 35 ng / ml can be suggested as predictor of heart failure decompensation in patients with AMI.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are